Pfizer to quit making biosimilar in China; sells out to WuXi

18 March 2021

China’s WuXi Biologics (HK: 2269) has entered into an equity agreement with US pharma giant Pfizer’s (NYSE: PFE) China subsidiary to acquire its state-of-the-art biologics manufacturing facilities, as well as its labor force in Hangzhou, China.

The transaction is expected to close in the first half of 2021, which will immediately boost the commercial drug substance (DS) and drug product (DP) capacities for WuXi Biologics to address surging manufacturing demands.

Both Pfizer and WuXi declined to disclose the deal value, or the products to be made after the transaction closes. However, back in 2016, Pfizer announced that it planned to invest about $350 million in the Hangzhou facility.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK